Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
Lancet. 2017.
PMID: 27932229
Clinical Trial.
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J.
Finn RS, et al. Among authors: baumhauer a.
J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.
J Hepatol. 2018.
PMID: 29704513
Clinical Trial.
Item in Clipboard
[Experimental studies of the no-reflow phenomenon with prostacyclin].
Frick AF, Baumhauer A, Baumeister RG, Wiebecke B.
Frick AF, et al. Among authors: baumhauer a.
Handchir Mikrochir Plast Chir. 1993 Nov;25(6):296-9.
Handchir Mikrochir Plast Chir. 1993.
PMID: 7507460
German.
Item in Clipboard
Cite
Cite